<DOC>
	<DOCNO>NCT00076024</DOCNO>
	<brief_summary>The primary purpose study determine time progression combination study drug ( AG-013736 ) docetaxel versus docetaxel alone patient receive prior chemotherapy metastatic breast cancer . The secondary purpose study determine dose study drug give docetaxel administer every 3 week schedule .</brief_summary>
	<brief_title>AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Female patient histologically/cytologically proven metastatic breast carcinoma ( stage IV , recurrent local regional spread distant metastatic disease ) Adequate bone marrow , liver , renal function Adjuvant chemotherapy give past 12 month Uncontrolled brain metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>metastatic breast cancer</keyword>
</DOC>